Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
NEW YORK - September 19, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
NEW YORK - September 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
NEW YORK - September 17, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
NEW YORK - September 16, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
NEW YORK - September 15, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company’s initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 and the Securities Exchange Act of 1934.
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024. Alto describes itself as a “clinical-stage biopharmaceutical company in the U.S.”
NEW YORK - September 12, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (NYSE: ANRO) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alto To Contact Him Directly To Discuss Their Options
